The Leukemia & Lymphoma Society (LLS) of White Plains, N.Y., has awarded 20 grants representing a total investment of $12 million to tackle four areas of high unmet medical need in the blood cancers.
LLS awarded the grants under its Translational Research Program, an initiative designed to help accelerate the movement of promising discoveries from the lab to the clinic. Each grant is for a three-year duration with a total value of $600,000.
The RFPs mark LLS's aggressive and proactive approach to addressing the challenge of improving outcomes for cancer patients with particularly urgent needs. LLS aims to stimulate more academic research in these areas: the malignant stem cells in acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS); non-cutaneous T-cell malignancies; high-risk myeloma; and long-term and late effects of blood cancer therapies.
Grants recipients in the area of leukemic stem cell in AML and MDS and the identification of potential targeted therapies:
Grants recipients in the area of novel therapeutic strategies for non-cutaneous T-cell lymphoproliferative disorders:
Grants recipients for the development of therapeutic strategies for the high risk myeloma patient:
Grant recipients for mechanisms underlying long term and late effects resulting from cancer treatment and the development of measures to significantly reduce or prevent these toxicities:
LLS also announced the awarding of an additional 28 TRP grants, totaling $15.6 million, to scientists working in other areas of blood cancer research.